Surface Modification with Pluronic P123 Enhances Transfection Efficiency of PAMAM Dendrimer

Xiang Wang; Xin Wu; Wei Fan; Baoyue Ding; Xiaoyu Wang; Wei Zhang; Xueying Ding; Jing Gao; Quangang Zhu; Jiyong Liu; Zhen Cai; Shen Gao

Macromolecular Research, Vol.20, No.2, 162-167, February, 2012

DOI10.1007/s13233-012-0031-4 Export Citation

Surface Modification with Pluronic P123 Enhances Transfection Efficiency of PAMAM Dendrimer

Xiang Wang^{1, 2}, Xin Wu^{1, 3}, Wei Fan^{4, 5}, Baoyue Ding^{1, 3}, Xiaoyu Wang^{1, 3}, Wei Zhang^{4, 6}, Xueying Ding⁷, Jing Gao⁷, Quangang Zhu^{1, 3}, Jiyong Liu^{1, 3}, Zhen Cai^{1, 3}, and Shen Gao^{1, 3, †}

¹Department of Pharmacy, Changhai Hospital, Second Military Medical University, Shanghai, P. R. China
²Department of Pharmacy, No. 98 Hospital of PLA, Huzhou, ZJ, P. R. China
³, China
⁴Department of Pharmacy, Changhai Hospital, Second Military Medical University, Shanghai, P. R. China
⁵Department of Pharmacy, No. 425 Hospital of PLA, Sanya, P. R. China
⁶Department of Pharmacy, No. 522 Hospital of PLA, Luoyang, HN, P. R. China
⁷Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai, P. R. China

E-mail:

To improve gene delivery efficiency and decrease cytotoxicity of polyamidoamine (PAMAM) polymers, P123-g-PAMAM was synthesized by modifying PAMAM with pluronic P123. The structure of the synthesized polymers was analyzed using proton nuclear magnetic resonance. The polymers were able to self-assemble with DNA, forming nanometer-scale complexes. Particle size measurement confirmed that the mean diameter of the polyplexes was 100-250 nm. The cytotoxicity and transfer efficiency were measured and compared with those of PEI and PAMAM. All of the polyplexes showed significantly low cytotoxicity in the MCF-7, HepG2, and 293T cell lines. In addition, the low level of P123 grafting to PAMAM showed significantly higher transfection efficiency than unmodified PAMAM at the optimal N/P ratio. These results suggest that P123-ylated PAMAM may prove as a useful carrier for gene delivery.

Keywords:gene delivery;polyamidoamine;transfection;cytotoxicity;pluronics.

[References]

Huang L, Hung MC, Wagner E, in Nonviral Vectors for Gene Therapy, Elsevier Academic Press, London, 3 (1999)
Kodama K, Latayama Y, Shoji Y, Nakashima H, Curr.Med. Chem., 13, 2155 (2006)
Park JS, Na K, Woo DG, Yang HN, Kim JM, Kim JH, Chung HM, Park KH, Biomaterials., 31, 124 (2010)
Kane NM, McRae S, Denning C, Baker AH, Drug Discov. Today Technol., 5, e107 (2008)
Schneeweiss A, Buyens K, Giese M, Sanders N, Ulbert S, Int. J. Pharm., 400, 86 (2010)
Hu Y, Li K, Wang L, Yin S, Zhang Z, Zhang Y, J.Control. Release., 144, 75 (2010)
Ditto AJ, Shah PN, Yun YH, Expert Opin. Drug Deliv., 6, 1149 (2009)
Anderson WF, Nature, 392(6679), 25 (1998)
Lee CC, Mackay JA, Szoka JF, Nat. Biotechnol., 23, 1517 (2005)
Nguyen HK, Lemieux P, Vinogradov SV, Gebhart CL, Guerin N, Paradis G, Bronich TK, Alakhov VY, Kabanov AV, Gene Ther., 7, 126 (2000)
Qi R, Gao Y, Tang Y, He RR, Liu TL, He Y, Sun S, Li BY, Li YB, Liu G, AAPS J., 11, 395 (2009)
Kircheis R, Wightman L, Schreiber A, Robitza B, Rossler V, Kursa M, Wagner E, Gene Ther., 8, 28 (2001)
Ogris M, Walker G, Blessing T, Kircheis R, Wolschek M, Wagner E, J. Control. Release., 72, 165 (2001)
Nam HY, Nam K, Hahn HJ, Kim BH, Lim HJ, Kim HJ, Choi JS, Park JS, Biomaterials., 30, 665 (2009)
Bromberg L, Alakhov VU, Hatton TA, Curr. Opin.Colloid Interface Sci., 11, 217 (2006)
Kabanov AV, Lemieux P, Vinofradov S, Alakhov V, Adv. Drug Deliv. Rev., 54, 223 (2002)
Ahn CH, Chae SY, Bae YH, Kim SW, J. Control.Release., 80, 273 (2002)
Kim YI, Seo HJ, Choi JS, Yoon JK, Baek JU, Kim K, Park JS, Bioconjug. Chem., 16, 1140 (2005)
Mukherjee SP, Davoren M, Byrne HJ, Toxicol. In Vitro., 24, 169 (2010)
Batrakova EV, Kabanov AV, J. Control. Release., 130, 98 (2008)
Demina T, Grozdova I, Krylova O, Zhirnov A, Istratov V, Frey H, Kautz H, Nubarov NM, Biochemistry., 44, 4042 (2005)
Alakhov VY, Kabanov AV, Expert Opin. Investig.Drugs., 7, 1453 (1998)

[1] Huang L, Hung MC, Wagner E, in Nonviral Vectors for Gene Therapy, Elsevier Academic Press, London, 3 (1999)

[2] Kodama K, Latayama Y, Shoji Y, Nakashima H, Curr.Med. Chem., 13, 2155 (2006)

[3] Park JS, Na K, Woo DG, Yang HN, Kim JM, Kim JH, Chung HM, Park KH, Biomaterials., 31, 124 (2010)

[4] Kane NM, McRae S, Denning C, Baker AH, Drug Discov. Today Technol., 5, e107 (2008)

[5] Schneeweiss A, Buyens K, Giese M, Sanders N, Ulbert S, Int. J. Pharm., 400, 86 (2010)

[6] Hu Y, Li K, Wang L, Yin S, Zhang Z, Zhang Y, J.Control. Release., 144, 75 (2010)

[7] Ditto AJ, Shah PN, Yun YH, Expert Opin. Drug Deliv., 6, 1149 (2009)

[8] Anderson WF, Nature, 392(6679), 25 (1998)

[9] Lee CC, Mackay JA, Szoka JF, Nat. Biotechnol., 23, 1517 (2005)

[10] Nguyen HK, Lemieux P, Vinogradov SV, Gebhart CL, Guerin N, Paradis G, Bronich TK, Alakhov VY, Kabanov AV, Gene Ther., 7, 126 (2000)

[11] Qi R, Gao Y, Tang Y, He RR, Liu TL, He Y, Sun S, Li BY, Li YB, Liu G, AAPS J., 11, 395 (2009)

[12] Kircheis R, Wightman L, Schreiber A, Robitza B, Rossler V, Kursa M, Wagner E, Gene Ther., 8, 28 (2001)

[13] Ogris M, Walker G, Blessing T, Kircheis R, Wolschek M, Wagner E, J. Control. Release., 72, 165 (2001)

[14] Nam HY, Nam K, Hahn HJ, Kim BH, Lim HJ, Kim HJ, Choi JS, Park JS, Biomaterials., 30, 665 (2009)

[15] Bromberg L, Alakhov VU, Hatton TA, Curr. Opin.Colloid Interface Sci., 11, 217 (2006)

[16] Kabanov AV, Lemieux P, Vinofradov S, Alakhov V, Adv. Drug Deliv. Rev., 54, 223 (2002)

[17] Ahn CH, Chae SY, Bae YH, Kim SW, J. Control.Release., 80, 273 (2002)

[18] Kim YI, Seo HJ, Choi JS, Yoon JK, Baek JU, Kim K, Park JS, Bioconjug. Chem., 16, 1140 (2005)

[19] Mukherjee SP, Davoren M, Byrne HJ, Toxicol. In Vitro., 24, 169 (2010)

[20] Batrakova EV, Kabanov AV, J. Control. Release., 130, 98 (2008)

[21] Demina T, Grozdova I, Krylova O, Zhirnov A, Istratov V, Frey H, Kautz H, Nubarov NM, Biochemistry., 44, 4042 (2005)

[22] Alakhov VY, Kabanov AV, Expert Opin. Investig.Drugs., 7, 1453 (1998)